Ϫ ) is augmented by increased endothelin-1 (ET-1) in deoxycorticosterone acetate (DOCA)-salt hypertension, a model of low renin hypertension. Tetrahydrobiopterin (BH 4 ), a potent reducing molecule with antioxidant properties and an essential cofactor for endothelial nitric oxide synthase, protects against O 2 Ϫ -induced vascular dysfunction. However, the interaction between O 2 Ϫ and BH 4 on endothelial function and the underlying mechanisms are unknown. Methods and Results-The present study tested the hypothesis that BH 4 deficiency due to ET-1-induced O 2 Ϫ leads to impaired endothelium-dependent relaxation and that gene transfer of human guanosine 5Ј-triphosphate (GTP) cyclohydrolase I (GTPCH I), the first and rate-limiting enzyme for BH 4 biosynthesis, reverses such deficiency and endothelial dysfunction in carotid arteries of DOCA-salt rats. There were significantly increased arterial O 2 Ϫ levels and decreased GTPCH I activity and BH 4 levels in DOCA-salt compared with sham rats. Treatment of arteries of DOCA-salt rats with the selective ET A receptor antagonist ABT-627, NADPH oxidase inhibitor apocynin, or superoxide dismutase (SOD) mimetic tempol abolished O 2 Ϫ and restored BH 4 levels. Basal arterial NO release and endothelium-dependent relaxations were impaired in DOCA-salt rats, conditions that were improved by apocynin or tempol treatment. Gene transfer of GTPCH I restored arterial GTPCH I activity and BH 4 levels, resulting in reduced O 2 Ϫ and improved endothelium-dependent relaxation and basal NO release in DOCA-salt rats.
T etrahydrobiopterin (BH 4 ) is an essential cofactor for endothelial nitric oxide synthase (eNOS). [1] [2] [3] [4] It is also a potent reducing molecule and has antioxidant activity for scavenging reactive oxygen species (ROS). 2 On the other hand, because BH 4 is a potent reducing molecule, it is also susceptible to oxidation under oxidative stress. Under physiological conditions, there is a balance between endothelial nitric oxide (NO) and superoxide (O 2 Ϫ ) production. However, when the BH 4 levels are insufficient, there is a shift of balance toward the production of O 2 Ϫ . 1, 2 Loss of BH 4 
availability causes formation of O 2
Ϫ instead of NO after eNOS activation and is an important contributor to endothelial dysfunction in cardiovascular diseases, including hypertension. [1] [2] [3] [4] [5] [6] A BH 4 deficiency results in endothelial dysfunction in hypertension, 5,6 diabetes, 7, 8 and atherosclerosis, 9 and BH 4 supplemen-tation improves endothelium-dependent vasodilation under these conditions. It has been hypothesized that either an increase in oxidative stress or a decrease of expression of guanosine 5Ј-triphosphate (GTP) cyclohydrolase I (GTPCH I), the first and rate-limiting enzyme for BH 4 biosynthesis, results in reduced BH 4 levels. However, the cellular mechanisms responsible for BH 4 deficiency remain to be delineated.
Arterial O 2 Ϫ levels are markedly increased in deoxycorticosterone acetate (DOCA)-salt hypertension 10 -15 (a model of low renin hypertension), resulting in endothelial dysfunction in carotid arteries. 16, 17 Our recent studies indicate that endothelin-1 (ET-1) plays an important role in NADPH oxidase-derived O 2 Ϫ production in this model. [13] [14] [15] However, the interaction between ET-1-induced O 2 Ϫ and BH 4 on endothelial dysfunction and the underlying mechanisms are unknown. In the present study, we tested the hypothesis that ET-1-induced O 2 Ϫ reduces BH 4 and endothelium-dependent relaxation in carotid arteries of DOCA-salt rats, and gene transfer of human GTPCH I reverses the BH 4 deficiency and endothelial dysfunction by reducing O 2 Ϫ levels. Our results indicate that a BH 4 deficiency due to ET-1-induced NADPH oxidase-derived O 2 Ϫ results in endothelial dysfunction, and that gene transfer of GTPCH I reverses the BH 4 deficiency and endothelial dysfunction by reducing O 2 Ϫ . These findings demonstrate a critical interaction between O 2 Ϫ and BH 4 on endothelial function, which may provide a mechanistic basis for regulating BH 4 levels as novel therapeutic strategies in cardiovascular disease.
Methods

DOCA-Salt Hypertensive Rats
DOCA-salt hypertension was created in adult male Sprague-Dawley rats as previously described. [13] [14] [15] Briefly, rats (250 to 275 g, Charles River, Portage, Mich) underwent uninephrectomy (flank incision, left side) and a silicon rubber DOCA implant (Sigma) (200 mg/kg) was placed subcutaneously between the shoulder blades. Sham rats were also uninephrectomized but received no implant. DOCA rats received 1.0% NaCl and 0.2% KCl in water to drink and sham rats received tap water. All animals were fed standard rat chow and had ad libitum access to both food and water. Hypertension develops gradually in this model, with arterial pressure slowly rising over a 4-week period. Blood pressure was measured using noninvasive tail cuff measurements in conscious but restrained and pre-warmed rats. Carotid arteries were collected between weeks 4 to 5 after DOCA implantation. All animal procedures were in accordance with institutional guidelines of Michigan State University.
In Vitro Pharmacological Interventions
Carotid arteries from normal rats were cut into ring segments (3 mm) and incubated at 37°C for 4 hours with or without ET-1 at increasing concentrations (0.1 to 10 nmol/L), or pretreated with the ET A receptor antagonist ABT-627 (30 nmol/L), the NADPH oxidase inhibitor apocynin (APO, 0.1 mmol/L), the xanthase oxidase inhibitor allopurinol (ALLO, 1 mol/L), the NOS inhibitor N-L-arginine methylester (L-NAME, 0.1 mmol/L), or the superoxide dismutase (SOD) mimetic tempol (TEM, 1 mmol/L) for 1 hour, respectively, before ET-1 (10 nmol/L, 4 hours) treatment. [13] [14] [15] Some arterial segments from sham and DOCA-salt rats were incubated at 37°C for 4 hours with or without the respective agents before O 2 Ϫ , BH 4 , and GTPCH I measurements.
Ex Vivo Gene Transfer
Arterial segments from sham and DOCA-salt rats were transduced with adenoviral vectors encoding human GTPCH I gene (AdGCH, 1x10 10 pfu/mL, Gen Vec, Inc) or ␤-gal reporter gene (AdLacZ) as previously described. [13] [14] [15] 18 The rings were then transferred to fresh Eagle minimal essential medium (EMEM) with 0.1% bovine serum albumin and incubated for 24 hours at 37°C. Some vessels from sham and DOCA-salt rats were incubated for 24 hours without transduction and served as normal negative controls. Transgene expression and function were assessed by Western blot analysis, measurements of BH 4 
level, GTPCH I activity, and O 2
Ϫ levels, as well as vascular reactivity.
Western Blot Analysis for GTPCH I Protein
Western blots were performed with a rabbit anti-human antibody (1:5000 dilution), 19 and a goat anti-rabbit immunoglobulin G secondary antibody (1:10 000 dilution, Oncogene Research Products, San Diego, Calif) as previously described. 18 -20 
HPLC Detection of BH 4 Level and GTPCH I Activity
Arterial BH 4 levels and GTPCH I activities were measured by high-performance liquid chromatography (HPLC) with florescence detection after iodine oxidation in acidic or alkaline conditions as previously described. 19, [21] [22] [23] [24] [25] Tissue was homogenized in cold extract buffer (50 mmol/L Tris-HCl of pH 7.4, 1 mmol/L DTT, 1 mmol/L EDTA), and centrifuged at 16 000g for 15 minutes at 4°C. Protein was removed by adding 10 L of a 1:1 mixture of 1.5 mol/L HClO 4 and 2 mol/L H 3 PO 4 to 90 L of extracts, followed by centrifugation.
To determine total biopterin (BH 4 , dihydropterin [BH 2 ], and oxidized biopterin) by acid oxidation, 10 L of 1% iodine in 2% KI solution was added to the 90 L protein-free supernatant. To determine BH 2 and oxidized biopterin by alkali oxidation, 10 L of 1 mol/L NaOH was added to 80 L of extract, then 10 L of 1% iodine in 2% KI solution was added. Samples were incubated at room temperature for 1 hour in the dark. Alkaline-oxidation samples were then acidified with 20 L of 1 mol/L H 3 PO 4 . Iodine was reduced by adding 5 L of fresh ascorbic acid (20 mg/mL). Samples of 50 L were injected into a 250-mm long, 4.6-mm-inner diameter Spherisorb ODS-1 column (5 m particle size; Alltech Associates, Inc) isocraticallyeluted with a methanol-water (5:95, v/v) mobile phase running at a flow rate of 1.0 mL/min. Fluorescence detection (350 nm excitation, 450 nm emission) was performed using a fluorescence detector (RF10AXL, Shimadzu Co). BH 4 concentrations, expressed as pmol/mg protein, were calculated by subtracting BH 2 plus oxidized biopterin from total biopterins. Similarly, GTPCH I activities were assayed according to the same HPLC method with measurement of neopterin, which was released from dihydroneopterin triphosphate after oxidation and phosphatase treatment. 22
Vascular O 2 ؊ Levels
Arterial O 2 Ϫ levels were assayed by oxidative dihydroethidium (DHE) fluorescence confocal microscopy and lucigenin (5 mol/L) chemiluminescence as described previously. [13] [14] [15] The oxidative fluorescent dye dihydroethidine was used to evaluate in situ O 2 Ϫ production. Unfixed frozen rings of carotid arteries were cut into 30 m sections and placed on a glass slide. Slides were incubated with dihydroethidium (1 mol/L) in a light-protected, humidified chamber at 37°C for 60 minutes and cover slipped. Tissue sections were then visualized with a Zeiss 210 confocal microscope with fluorescence detected with a 590 nm long-pass filter, and images were collected and stored digitally. Red signal in tissue section represents O 2 Ϫ level.
Basal NO Levels
Basal NO release was estimated by nitrite (a stable NO metabolite) accumulation in EMEM after 24-hour incubation of carotid arteries with Griess Reagent (Sigma). 26 EMEM incubation media without blood vessels were used as negative controls. To determine the calcium-dependent NO release, both an extracellular calcium chelator (EGTA, 1 mmol/L, Sigma) and an intracellular calcium chelator (BAPTA/AM, 20 mol/L, Calbiochem) were added to EMEM. 18, 20 Calcium-dependent NO release was estimated as the difference between samples incubated with and without calcium chelators. After 24 hours incubation, EMEM was subjected to determination of nitrite with NaNO 2 as standard.
Vascular Reactivity
Vascular reactivity studies were performed in arterial ring segments as we previously described. 18, 20 In preliminary studies, the optimal tension of the carotid arteries from both sham and DOCA-salt rats in response to KCl stimulation was determined to be 1.5 g. Rings were connected to isometric transducers (Radnoti Grass Technology Inc) and suspended in organ chambers filled with 15 mL of gassed (95% O 2 , 5% CO 2 ) Krebs solution (pH 7.4, 37°C) composed of (in mmol/L) 118.3 NaCl, 4.7 KCl, 2.5 CaCl 2 , 1.2 MgSO 4 , 1.2 KH 2 PO 4 , 25.0 NaHCO 3 , 0.0026 EDTA, and 11.1 glucose. Isometric tension was recorded continuously. Arteries were allowed to equilibrate for 30 minutes and were then gradually stretched to 1.5 g tension over 40 minutes. After 2 challenges with 60 mmol/L KCl, 10 mol/L of indomethacin was added to eliminate the influence of endogenous cyclooxygenase before the submaximal contractions induced by thromboxane A 2 analogue 9, 11-dideoxy-11a,9a-epoxymethanoprostaglandin F 2 (U46619, 1 to 100 nmol/L). After a stable contraction plateau was reached, acetylcholine (endotheliumdependent, 1 nmol to 10 mol/L) or sodium nitroprusside (endotheliumindependent, 1 nmol to 10 mol/L)-induced relaxations were performed. The relaxations were expressed as a percentage of maximal relaxations induced by papaverine (0.1 mol/L). In some experiments, arteries were incubated with NOS inhibitor N-nitro-L-arginine (L-NNA, 0.1 mmol/L, 30 minutes), tempol (1 mmol/L, 15 minutes), or apocynin (0.1 mmol/L, 30 minutes) before the relaxation experiments. All the relaxation responses in control arteries were obtained after a 24-hour incubation period in minimal essential medium (EMEM), which was needed to compare with the responses in 24-hour transduced arteries.
Drugs
Acetylcholine, indomethacin, sodium nitroprusside, and papaverine were purchased from Sigma and dissolved in saline. U46619 was purchased from Cayman Chemical and dissolved in 100% ethanol. Subsequent dilutions were made with saline. Dihydroethidium was purchased from Molecular Probes and dissolved in 0.1 mol/L DMSO.
Statistical Analyses
Data were expressed as mean Ϯ SEM. Repeated measures ANOVA was used for comparison of multiple values obtained from the same subject, whereas factorial ANOVA was used for comparing data obtained from 2 independent samples of subjects. Bonferroni's procedure was used to control type I error. A value of PϽ0.05 was considered significant.
Results
ET-1 Increases Arterial O 2 ؊ Levels via an ET A /NADPH Oxidase Pathway
Ϫ levels in carotid arteries of normal Sprague-Dawley rats were significantly increased in a concentration-dependent manner after treatment with ET-1 for 4 hours ( Figure 1A , nϭ6; PϽ0.01). The effect of ET-1 treatment (10 nmol/L) was abolished by pretreatment with the selective ET A receptor antagonist ABT-627 (nϭ5; PϽ0.05), the NADPH oxidase inhibitor apocynin (nϭ5; PϽ0.05), or the SOD mimetic tempol (nϭ5; PϽ0.05), but not by the NOS inhibitor L-NAME (nϭ5; PϾ0.05) or the xanthine oxidase inhibitor allopurinol (nϭ5; PϾ0.05) ( Figure 1B ). Treatment of carotid arteries of normal rats with ABT-627, apocynin, tempol, L-NAME, or allopurinol did not alter basal O 2 Ϫ levels (data not shown). There were also significantly increased arterial O 2 Ϫ levels (nϭ6; PϽ0.01) in carotid arteries of DOCA-salt rats compared with sham rats ( Figure 1C ). Treatment of carotid arteries of DOCA-salt rats with ABT-627, apocynin, or tempol abolished O 2
Ϫ increase (nϭ5 to 6; PϽ0.05). In contrast, neither L-NAME nor allopurinol had any effects on O 2
Ϫ levels (nϭ5 to 6; PϾ0.05). Treatment of carotid arteries of sham rats with ABT-627, apocynin, tempol, L-NAME, or allopurinol did not alter basal O 2 Ϫ levels (data not shown).
ET-1-Induced O 2 ؊ Decreases Arterial BH 4 Levels
ET-1 treatment of carotid arteries of normal rats (10 nmol/L, 4 hours) significantly reduced BH 4 levels ( Figure  2A, nϭ5; PϽ0.01) , an effect that was prevented by pretreatment with ABT-627 (nϭ5; PϽ0.05), apocynin (nϭ5; PϽ0.05), or tempol (nϭ5; PϽ0.05), but not by L-NAME (nϭ5; PϾ0.05) or allopurinol (nϭ5; PϾ0.05) (Figure 2A ). Treatment of carotid arteries of normal rats with only ABT-627, apocynin, tempol, L-NAME, or allopurinol did not alter basal BH 4 levels (data not shown).
There were significantly decreased arterial BH 4 levels (nϭ5; PϽ0.05) in carotid arteries of DOCA-salt rats as compared with sham rats ( Figure 2B ). Treatment of carotid arteries of DOCA-salt rats with ABT-627, apocynin, or tempol restored BH 4 levels (nϭ5 to 6; PϽ0.05). L-NAME Figure 1 . Effect of ET-1 on arterial O 2 Ϫ levels. A, Carotid arteries of normal rats were incubated at 37°C for 4 hours without or with ET-1 at increasing concentrations (nϭ5 to 6; *PϽ0.01 versus control). B, Arteries of normal rats were pretreated with ABT-627 (30 nmol/L), apocynin (APO, 0.1 mmol/L), allopurinol (ALLO, 1 mol/L), L-NAME, (0.1 mmol/L), or tempol (TEM, 1 mmol/L) for 1 hour before ET-1 (10 nmol/L, 4 hours) treatment (nϭ5; *PϽ0.05 versus ET-1 10 nmol/L treatment). C, Arteries of DOCA-salt rats were incubated at 37°C for 4 hours without or with ABT-627, APO, ALLO, L-NAME, or tempol at the same concentrations as above (nϭ5 to 6; *PϽ0.05 versus DOCA). Arteries were subjected to O 2 Ϫ measurement by lucigeninenhanced chemiluminescence. and allopurinol had no effect on BH 4 levels (nϭ5 to 6; PϾ0.05). Treatment of carotid arteries of sham rats with ABT-627, apocynin, tempol, L-NAME, or allopurinol did not alter basal BH 4 levels (data not shown).
Effect of Gene Transfer of Human GTPCH I on Arterial GTPCH I, BH 4 , and O 2 ؊ Levels
To demonstrate transgene expression, carotid arteries of sham and DOCA-salt rats were analyzed by Western blotting for human GTPCH I protein. A rabbit anti-human GTPCH I primary antibody (1:5000 dilution) 19 was used to recognize recombinant protein expressed by human GTPCH I gene that had been integrated into the AdGCH viral vectors. Typical immunoblot images revealed significant GTPCH I bands in AdGCH-transduced arteries but not in AdLacZ-transduced or non-transduced controls ( Figure 3A ). There were significantly decreased GTPCH I activities ( Figure  3B ) and BH 4 levels ( Figure 3C ) in carotid arteries of DOCA-salt rats compared with those of sham rats. After gene transfer of GTPCH I, arteries of both DOCA-salt (nϭ5; PϽ0.01) and sham rats (nϭ5; PϽ0.01) demonstrated a significant elevation of GTPCH I activities ( Figure 3B ) and BH 4 levels ( Figure 3C ) compared with AdLacZ-transduced or non-transduced control arteries.
In situ detection of O 2 Ϫ indicated that the dihydroethidine signal in arteries of DOCA-salt rats was markedly more prominent than that in sham rats, which was suppressed after AdGCH but not AdLacZ transduction ( Figure 4A ). Quantitatively, gene transfer of AdGCH but not AdLacZ resulted in significantly diminished O 2
Ϫ levels in arteries of DOCA-salt rats (nϭ6; PϽ0.05) ( Figure 4B ). 
Treatment With Apocynin and Tempol, or Gene Transfer of GTPCH I Improves Endothelium-Dependent Relaxations in Carotid Arteries of DOCA-Salt Rats
Endothelium-dependent relaxations to acetylcholine (1 nmol to 10 mol/L) were significantly reduced in carotid arteries of DOCA-salt rats compared with those of sham rats (nϭ5 to 6; PϽ0.05) ( Figure 5A ). Acetylcholine produced 68.32Ϯ6.01% of maximal relaxations in sham rats compared with 40.5Ϯ3.7% of maximal relaxations in DOCA-salt rats (PϽ0.05), which were attenuated by preincubation with NOS inhibitor L-NNA. Preincubation with the NADPH oxidase inhibitor apocynin or SOD mimetic tempol significantly improved endothelium-dependent relaxations in arteries of DOCA-salt rats (nϭ5 to 6; PϽ0.05) ( Figure 5A ). There was Ϫ levels were measured by lucigenin-enhanced chemiluminescence. Carotid arteries were harvested after incubation with blank EMEM (control), 1ϫ10 10 pfu/mL AdLacZ, or 1ϫ10 10 pfu/mL AdGCH for 4 hours followed by incubation in fresh EMEM for 24 hours (nϭ5 to 6). *PϽ0.01 versus sham control and DOCAϩAdGCH. Figure 5 . Concentration-response curves of endotheliumdependent relaxations to acetylcholine by arteries of DOCA-salt and sham rats. Arteries of DOCA-salt and sham rats were subjected to isometric tension recording studies. The relaxations were expressed as a percentage of maximal relaxations induced by papaverine (0.1 mmol/L). A, Some arteries were preincubated with L-NNA (300 mol/L, 30 minutes), apocynin (100 mol/L, 30 minutes), or tempol (1 mmol/L, 15 minutes) before relaxations were induced (nϭ5 to 6). *PϽ0.05 versus other groups. B and C, Effects of gene transfer of GTPCH I on relaxation responses to acetylcholine by arteries of sham and DOCAsalt rats exposed to blank EMEM, AdLacZ, and AdGCH (nϭ5 to 6). *PϽ0.05 versus DOCA control and DOCAϩAdLacZ. Please note that all the relaxation responses in control arteries were obtained after a 24-hour incubation period in minimal essential medium (EMEM), which was needed to compare with the responses in 24-hour transduced arteries. no significant difference in the relaxation in arteries of DOCA-salt rats compared with those of sham rats when treated with sodium nitroprusside (data not shown).
Gene transfer of AdGCH but not AdLacZ significantly improved endothelium-dependent relaxations in DOCA-salt but not sham rats ( Figure 5B and 5C, nϭ5 to 6; PϽ0.05). The relaxations of AdGCH-transduced arteries of either DOCAsalt or sham rats to sodium nitroprusside were not different compared with those of AdLacZ-transduced controls (data not shown). It is important to note that all relaxation responses in control arteries were obtained after a 24-hour incubation period in minimal essential medium, which was needed to compare with the responses in 24-hour transduced arteries. As a result, the acetylcholine-induced maximal relaxation in control arteries was around 60%, which has been shown to be due to the effect of 24-hour incubation in minimal essential medium. 18
Gene Transfer of GTPCH I Increases Basal NO Release in Arteries of DOCA-Salt Rats
Basal NO levels, detected as calcium-dependent NO 2 production, were shown as the difference between NO 2 levels with and without calcium chelator treatment. Basal NO production was significantly lower in arteries of DOCA-salt rats than in sham rats (nϭ5; PϽ0.05) ( Figure 6 ). AdGCH-transduced arteries of DOCA-salt rats exhibited significantly elevated NO levels compared with AdLacZ-transduced or nontransduced controls (nϭ6; PϽ0.01). There were no significant elevations of basal NO levels in AdGCH-transduced arteries of sham rats compared with those of AdLacZtransduced or non-transduced controls (nϭ5 to 6; PϾ0.05).
Discussion
In the present study, there are 3 major new findings. First, arterial GTPCH I activity was decreased and BH 4 was deficient in DOCA-salt rats. Second, arterial BH 4 levels were restored after inhibition of ET A -receptors, NADPH oxidase, or O 2 Ϫ itself. Inhibition of NADPH oxidase or O 2 Ϫ also improved endothelium-dependent relaxations, which were impaired in carotid arteries of DOCA-salt rats. Finally, gene transfer of human GTPCH I restored arterial GTPCH I activity and BH 4 levels, with a subsequent reduction of O 2 Ϫ levels, augmentation of basal NO levels, and improvement of endothelium-dependent relaxations.
Several recent studies have shown that arterial O 2 Ϫ levels are markedly increased in salt-sensitive hypertension of both human and animal models, including DOCA-salt hypertension, 10 -15 a model with suppressed plasma renin level in which ET-1 has been implicated in the development and maintenance of hypertension. [27] [28] [29] Our recent study 14 has demonstrated that the ET-1 levels in carotid arteries of DOCA-salt rats are markedly increased, which contributes to O 2
Ϫ production via an ET A /NADPH oxidase pathway. The present study extends further these findings that (1) ET-1 increases O 2
Ϫ levels in a concentration-dependent manner in carotid arteries of normal rats, (2) the selective ET A receptor antagonist ABT-627, NADPH oxidase inhibitor apocynin, and SOD mimetic tempol, but not xanthine oxidase inhibitor allopurinol or NOS inhibitor L-NAME, suppressed the O 2 Ϫ levels in both ET-1-stimulated arteries of normal rats and arteries of DOCA-salt rats, and (3) inhibition of either NADPH oxidase or O 2
Ϫ itself led to improved endotheliumdependent NO-mediated relaxations.
An arterial BH 4 deficiency exists in cardiovascular diseases, including hypertension, 5,6 diabetes, 7, 8 hypercholesterolemia and therosclerosis, 9,30 -32 and chronic smoking, 33 resulting in impaired endothelium-dependent NO-mediated vasodilations. However, the cellular mechanisms underlying BH 4 deficiency are not well understood. 1, 2 In mammalian cells, BH 4 is synthesized through 2 distinct pathways. 34 One is the de novo synthetic pathway in which the precursor GTP is catalyzed by the first and rate-limiting enzyme GTPCH I to dihydroneopterin triphosphate, whereby BH 4 is then generated by further steps involving 6-pyruvoltetrahydropterin synthase and sepiapterin reductase. Recently, reduced expression and activity of GTPCH I have been shown in coronary endothelial cells of diabetic rats and aortas of insulin-resistant rats, resulting in diminished BH 4 levels. 7, 8 The other pathway of BH 4 synthesis is the regeneration of BH 4 from BH 2 through a pterin salvage pathway, which is independent of GTPCH I but depends on a normal cellular redox state. It has been reported that BH 4 can rapidly be oxidized to BH 2 by peroxynitrite, and regeneration of BH 2 to BH 4 is impaired by oxidative stress. 5, 7, 9 Chronic treatment with antioxidants restores arterial BH 4 levels in apolipoprotein-E knockout mice. 24 An important question that remains to be answered is how the DOCA-salt hypertensive state affects BH 4 levels. The present study demonstrated that arterial BH 4 levels were reduced by ET-1-induced O 2 Ϫ and inhibition of ET A receptors, NADPH oxidase, or removal of O 2
Ϫ restored BH 4 levels in DOCA-salt hypertensive rats. Furthermore, the present study is the first to show that arterial GTPCH I activities were significantly decreased in this model. As illustrated in Figure  7 , our findings indicate that both decreased GTPCH I activity and increased O 2 Ϫ contribute to the observed BH 4 deficiency in DOCA-salt hypertensive rats. These results extend a recent report that peroxynitrite oxidizes BH 4 in DOCA-salt mice. 5 These data are also consistent with the observations obtained Figure 6 . Effect of gene transfer of GTPCH I on basal NO production. After carotid arteries were incubated with blank EMEM (control), 1ϫ10 10 pfu/mL AdLacZ, or 1ϫ10 10 pfu/mL AdGCH for 4 hours followed by incubation with or without extracellular calcium chelator EGTA and intracellular calcium chelator BAPTA/AM for 24 hours, culture medium was collected and basal NO production was determined by nitrite accumulation in the medium. Basal NO levels, detected as calcium-dependent NO 2 production, were shown as the difference between NO 2 levels with and without calcium chelator treatment (nϭ5). *PϽ0.01 versus sham control and DOCAϩAdGCH.
in BH 4 -deficient mice that increased oxidative stress is SOD-sensitive and contributes to a hypertensive phenotype, 33 and they illustrate the complex mechanisms underlying reduced BH 4 levels in cardiovascular disease.
Relative deficiency of BH 4 has been suggested to be a major cause of impaired endothelium-dependent relaxation, 2 and BH 4 supplementation has been shown to improve endothelium-dependent relaxations by preserving endogenous NO production in vitro and in vivo. 3,7,23,30 -33 In agreement with this concept, the present study demonstrates that ex vivo gene transfer of human GTPCH I resulted in recombinant GTPCH I protein expression and restoration of both GTPCH I enzymatic activities and BH 4 levels in carotid arteries of DOCA-salt rats. Most importantly, O 2 Ϫ levels were diminished in GTPCH I-transduced arteries with a concomitant increase of calcium-sensitive NO production and improvement of endothelium-dependent relaxations. Together, these findings indicate a demonstrable functional effect of GTPCH I gene transfer. Because the carotid arteries of DOCA-salt rats exhibited a sensitivity to sodium nitroprusside (a NO donor)induced endothelium-independent relaxation similar to that of sham rats, the smooth muscle sensitivities to NO of carotid arteries of DOCA-salt and sham rats are not different. Thus, the observed endothelial dysfunction was most likely due to the loss of endothelium-derived NO. The latter may result from a decreased NO biosynthesis as a result of O 2 Ϫ oxidation of BH 4 
and/or an inactivation of NO by O 2
Ϫ . Because pterins (including BH 4 ) possess antioxidant property by virtue of their scavenging activity for reactive oxygen species, 32, 35 decreased levels of BH 4 may lead to increased O 2 Ϫ formation and endothelial dysfunction. By restoring the BH 4 levels, gene transfer of GTPCH I may exert its beneficial effects via increasing the direct antioxidant effect of BH 4 and thereby shifting the imbalance between O 2
Ϫ and NO and/or enhancing physiological eNOS function, which is known to preserve endothelium-dependent relaxations.
In conclusion, our findings demonstrate that (1) a BH 4 deficiency resulting from ET-1-induced O 2
Ϫ via an ET A / NADPH oxidase pathway contributes to endothelial dysfunction and (2) gene transfer of human GTPCH I reverses BH 4 deficiency and suppresses O 2 Ϫ levels, with a subsequent restoration of endothelial function in low renin mineralocorticoid hypertension. These results may provide a mechanistic basis for therapeutic strategies aimed at increasing vascular BH 4 levels for therapy of endothelial dysfunction in cardiovascular disease, including hypertension. 
